France-based biopharmaceutical firms Stallergenes and DBV Technologies have entered into a research and development agreement for the treatment of birch allergy. Stallergenes is specialized in the manufacturing of immunotherapy medicines ...
DBV Technologies and Stallergenes have entered into a strategic research partnership to develop immunotherapy treatments for respiratory allergies using DBV's skin patch, Viaskin. The collaboration combines Stallergenes' know-how in ...
Ares Life Sciences, a Switzerland-based healthcare-focused investment group, has signed a definitive agreement to acquire the complete share capital of Planet Biopharmaceuticals. The agreement also includes the acquisition of Planet ...
Tags: Ares Life Sciences, Medicine